In a double-blind , randomized , placebo-controlled , two-period crossover study , patients with type 2 diabetes with inadequate glycaemic control on metformin monotherapy ( i.e. on a stable dose of > or = 1500 mg/day for > or = 6 weeks prior to the screening visit and an haemoglobin A ( 1c ) ( HbA ( 1c ) ) > or = 6.5 % and < 10 % and fasting plasma glucose ( FPG ) < or = 240 mg/dl ) were recruited for participation .
